{"eventGroups":[{"description":"Participants receive ipilimumab intratumorally on Day 1\n\nIpilimumab: Given intratumorally","id":"EG000","otherNumAffected":1,"otherNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"title":"Ipilimumab 25 mg"},{"description":"Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions\n\nIpilimumab: Given intratumorally\n\nRadiation therapy: Undergo local radiation therapy, 10 Gy x 3 fractions","id":"EG001","otherNumAffected":0,"otherNumAtRisk":0,"seriousNumAffected":0,"seriousNumAtRisk":0,"title":"Ipilimumab 25 mg and Radiation Therapy"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE 4","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":3,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":0,"numEvents":0}],"term":"Pain, injection site"}]}